OTR3

Biotechnology Research • Paris, Île-de-France, France • 21-50 Employees

Company overview

Headquarters	4, rue Française, Paris, 75001, FR
Phone number	+33183642300
Website	otr3.com
SIC	873
Keywords	Healing, Regenerative Medicine, Chronic Wounds, Ards, Ischemic Stroke, Cacicol20®, Cacipliq20®, Corneal Lesions, Matrix Therapy, Regenerating Agents, Rgta®
Employees	21-50
Socials

Key Contact at OTR3

Audrey Arrivetx

Marketing & Communication Director

OTR3 Email Formats

OTR3 uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@otr3.com), used 60% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@otr3.com	60%
{first name}.{last name}	john.doe@otr3.com	40%

About OTR3

OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on RGTA® (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates. After an injury, RGTA® target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and corneal ulcers. OTR3's Pipeline include innovative therapeutic products for ischemic stroke (Project awarded a H2020 SME Instrument grant), Acute respiratory distress syndrome (ARDS) and chronic ulcer for epidermolysis bullosa (Project awarded a PIA Leader Innov'Up grant).

OTR3 revenue & valuation

Annual revenue	$2,053,320
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$6,600,000
Total funding	$3,900,000